Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant QT/QTc study in healthy adults
NCT03494907Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of seltorexant in major depressive disorder (MDD) and Insomnia (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change From Baseline in QT/QTc Intervals at Day 3, Percentage of Participants with Change from Baseline in T-wave Morphology at Day 3 and 1 more. Started Apr 2018; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT03494907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03494907.